PHOENIX--(BUSINESS WIRE)--Zila, Inc. (NASDAQ:ZILA) today said it has completed the first phase of the global rollout for its proprietary oral cancer screening product, ViziLite® Plus with TBlue®. Beginning in North America and through its direct sales force, Zila now markets ViziLite Plus in all 50 states of the U.S., as well as Puerto Rico and Canada. Since May 2008, the company expanded to Western Europe by forming strategic alliances to distribute ViziLite Plus in a number of European markets. Currently, the product is available in the United Kingdom, Ireland, Germany, Spain, Portugal, France and Greece. In the next phase of its expansion, the company has formed distribution agreements in other international markets, including Russia and Belarus, where product registration is in process. These markets and others in the Pacific Rim region, especially China and India, will form the bulk of the company’s continued global expansion for ViziLite Plus.
